LNSR vs. DCTH, NPCE, PROF, DRTS, ARAY, CLPT, CVRX, TELA, QIPT, and KRMD
Should you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include Delcath Systems (DCTH), NeuroPace (NPCE), Profound Medical (PROF), Alpha Tau Medical (DRTS), Accuray (ARAY), ClearPoint Neuro (CLPT), CVRx (CVRX), TELA Bio (TELA), Quipt Home Medical (QIPT), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 17.9% of Delcath Systems shares are held by insiders. Comparatively, 38.5% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
LENSAR has higher revenue and earnings than Delcath Systems. LENSAR is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Delcath Systems currently has a consensus target price of $20.20, suggesting a potential upside of 186.52%. LENSAR has a consensus target price of $8.00, suggesting a potential upside of 70.21%. Given LENSAR's higher possible upside, research analysts clearly believe Delcath Systems is more favorable than LENSAR.
Delcath Systems has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
In the previous week, Delcath Systems had 1 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for Delcath Systems and 2 mentions for LENSAR. LENSAR's average media sentiment score of 1.79 beat Delcath Systems' score of 0.92 indicating that Delcath Systems is being referred to more favorably in the media.
LENSAR has a net margin of -27.57% compared to LENSAR's net margin of -1,080.72%. Delcath Systems' return on equity of -36.53% beat LENSAR's return on equity.
Delcath Systems received 18 more outperform votes than LENSAR when rated by MarketBeat users. However, 38.46% of users gave LENSAR an outperform vote while only 22.33% of users gave Delcath Systems an outperform vote.
Summary
Delcath Systems beats LENSAR on 9 of the 17 factors compared between the two stocks.
Get LENSAR News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
